Biodexa announces enrollment of first two patients in Phase 3 Serenta trial

Biodexa Pharmaceuticals (BDRX) announces the enrollment of the first two patients by the Pan American Center for Oncology Trials in San Juan, Puerto Rico into its pivotal Phase 3 Serenta trial of eRapa in patients with familial adenomatous polyposis, a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer. Commenting, Stephen Stamp CEO and CFO of Biodexa said “Enrolling the first patients in our pivotal Phase 3 study in FAP is a seminal event for our company, our collaborator Emtora Biosciences and our CRO, LumaBridge. As the only drug candidate for FAP in Phase 3, our combined team is committed to advancing eRapa as the first non-surgical treatment for the thousands of patients worldwide suffering from this debilitating disease. We recognize both the responsibility and the opportunity to be the first mover in this $7 billion addressable market. And none of this would have been possible without the support of CPRIT which has awarded $20 million in grant funding to support the program”.